IBM-The Importance Of Early Key Opinion Leader Outreach In The Biologics And Biosimilars Marketplace

Over the past several years, the pharmaceutical industry has witnessed significant growth in the biologics sector, with biologics representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market. In reality though, the impact of biosimilar entry is not necessarily purely economic. Due to the myriad forms of intellectual property incorporated into many biologics—proprietary cell lines, formulation processes and the like—a biosimilar is just that: similar, but not identical, to the branded product it hopes to supplant. The salient question to ask of any potential biosimilar entrant is this: Just how similar is similar? Download to Learn More.
Download this webcast to learn more

By submitting this form, you agree to have your contact information passed along for the purpose of following up on your interests and in order receive communications regarding IBM products, services, and events. The data sent will be processed in Canada and provided to IBM who will assume responsibility for processing and Opt-out and Information Removal. For more information, please read our Terms of Use, Privacy, Opt-out & Information Removal below.